ABSTRACT
Liver cirrhosis is an end-stage fibrotic disease of chronic liver injury induced by various factors. Many studies have shown that gut microbiota (GM) are involved in the development and progression of liver cirrhosis and related complications, such as portal hypertension, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatocellular carcinoma. In addition, impaired intestinal barrier, compromised liver immunity, and bacterial translocation play a critical role in the progression of liver cirrhosis. This article summarizes the role of GM in liver cirrhosis and related complications and research advances and problems in GM as a therapeutic target, in order to provide new thoughts for clinical diagnosis and treatment.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD)is a clinicopathological syndrome characterized by diffuse macrovesicular steatosis in hepatocytes and is caused by the factors except excessive drinking and other specific factors for liver injury. In particular,lipid metabolism disorder is a significant characteristic of NAFLD,and improvement of dyslipidemia is an important method for the prevention and treatment of NAFLD. Lipid - regulating drugs can not only reduce blood lipids,but also promote the transportation of lipids to the liver for metabolism, which may cause liver lipid accumulation and aggravate liver injury. At present,there are still controversies over the application of lipid -regulating drugs in the treatment of NAFLD in China. Rational use of lipid - regulating drugs has become an important topic in the prevention and treatment of NAFLD. This article summarizes the application of lipid - regulating drugs in NAFLD,in order to provide a reference for lipid - regulating drugs in the prevention and treatment of NAFLD.